[{"id":"6875ca53-6d3a-4295-900b-d9b68a43e3c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04989946","created_at":"2023-12-21T18:18:35.344Z","updated_at":"2025-02-25T14:16:15.460Z","phase":"Phase 1/2","brief_title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","source_id_and_acronym":"NCT04989946","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Libtayo (cemiplimab-rwlc) • Firmagon (degarelix) • fianlimab (REGN3767) • MVI-118"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-07"},{"id":"c54aeb23-834a-4c49-9030-ec1b4fe12e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05800015","created_at":"2023-04-05T14:03:34.879Z","updated_at":"2025-02-25T17:26:07.111Z","phase":"Phase 2/3","brief_title":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05800015","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)"],"overall_status":"Recruiting","enrollment":" Enrollment 950","initiation":"Initiation: 08/08/2023","start_date":" 08/08/2023","primary_txt":" Primary completion: 01/16/2030","primary_completion_date":" 01/16/2030","study_txt":" Completion: 12/23/2031","study_completion_date":" 12/23/2031","last_update_posted":"2025-01-31"},{"id":"a2aa78c5-6c40-4253-8db6-d0f14ce0af71","acronym":"","url":"https://clinicaltrials.gov/study/NCT06769698","created_at":"2025-02-26T07:08:07.434Z","updated_at":"2025-02-26T07:08:07.434Z","phase":"Phase 2","brief_title":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06769698","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/26/2025","start_date":" 03/26/2025","primary_txt":" Primary completion: 04/22/2027","primary_completion_date":" 04/22/2027","study_txt":" Completion: 11/28/2029","study_completion_date":" 11/28/2029","last_update_posted":"2025-01-10"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"865eb16a-cc7f-4591-a2db-0411186bb497","acronym":"R3767-ONC-2235","url":"https://clinicaltrials.gov/study/NCT05785767","created_at":"2023-03-27T20:03:40.832Z","updated_at":"2024-07-02T16:35:00.454Z","phase":"Phase 2/3","brief_title":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05785767 - R3767-ONC-2235","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)"],"overall_status":"Recruiting","enrollment":" Enrollment 850","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 03/11/2030","primary_completion_date":" 03/11/2030","study_txt":" Completion: 02/05/2032","study_completion_date":" 02/05/2032","last_update_posted":"2024-05-29"},{"id":"1418a6c5-fd7e-4f45-9af7-c21d6ef0bb58","acronym":"","url":"https://clinicaltrials.gov/study/NCT04566978","created_at":"2021-01-18T21:48:55.475Z","updated_at":"2024-07-02T16:35:33.079Z","phase":"Phase 1","brief_title":"89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT04566978","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" LAG3","pipe":" | ","alterations":" LAG3 expression","tags":["LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LAG3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fianlimab (REGN3767)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 09/11/2020","start_date":" 09/11/2020","primary_txt":" Primary completion: 09/11/2025","primary_completion_date":" 09/11/2025","study_txt":" Completion: 09/11/2025","study_completion_date":" 09/11/2025","last_update_posted":"2023-10-17"}]